Product Description
For Parkinson's Disease (PD)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Texas Health Science Center, Houston
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Clostridium Infections|Parkinson's Disease|Inflammation|Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic|Colitis, Ulcerative|Fatty Liver, Alcoholic|Hepatitis A|Hepatitis, Alcoholic
Phase 1: Parkinson's Disease|Colitis, Ulcerative|HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HSC-MS-23-0016 | P1 |
Recruiting |
Colitis, Ulcerative |
2026-12-15 |
|
HSC-MS-20-0316 | P2 |
Recruiting |
Colitis, Ulcerative|Inflammation |
2025-12-31 |
|
H-43752 | P2 |
Recruiting |
Hepatitis A|Hepatitis, Alcoholic |
2025-06-30 |
|
HSC-SPH-19-1126 | P2 |
Withdrawn |
Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic |
2024-12-01 |